Carcinosarcoma

This is a rare type of cancer that contains both cancerous cells from glands (carcinoma) and cancerous cells from connective tissue (sarcoma). It's a mixed type of cancer.

Condition

What people with Carcinosarcoma report

Every report comes from a Lived member, sent anonymously.

Have you had Hysterectomy for Carcinosarcoma?

NameHow it went

About Carcinosarcoma

What It Is

Carcinosarcoma is a rare, aggressive cancer made of two kinds of cancer cells mixed together. One part is carcinoma, cancer of the cells that line organs. The other is sarcoma, cancer that looks like connective tissue such as muscle, cartilage or bone. Because both appear in a single tumor, it was once called a malignant mixed Müllerian tumor (MMMT), a name some reports still use. Carcinosarcoma can arise in several organs, including the lung and pancreas, but it is best known and best studied in the uterus, with the ovary next. Most of what follows concerns uterine carcinosarcoma. Doctors now understand it as a high-grade form of endometrial cancer (cancer of the uterine lining) in which the carcinoma part drives how the disease behaves. That matters because it tends to spread beyond the uterus earlier than more common endometrial cancers, so it is treated more intensively from the start.

Causes & Risk Factors

Researchers do not know exactly why carcinosarcoma develops. The sarcoma-like cells appear to grow out of the carcinoma cells as the tumor changes, rather than being a second, separate cancer. Uterine carcinosarcoma occurs mostly after menopause, often around age 70. Factors linked to endometrial cancer in general, such as obesity, long-term estrogen therapy without a progestin, and inherited conditions such as Lynch syndrome, are also considered relevant. Tamoxifen, a hormone medicine used to treat or prevent breast cancer, slightly raises the risk of uterine cancers, including rare carcinosarcomas; for people who already have breast cancer, its benefits generally outweigh this risk. Earlier radiation therapy to the pelvis, for example for cervical cancer, has been linked to later carcinosarcoma, sometimes many years afterward. In the United States, Black women are two to three times more likely than white women to develop uterine carcinosarcoma, for reasons that are not fully understood. Ovarian carcinosarcoma shares some risk factors with other ovarian cancers, including older age and inherited variants in the BRCA1 or BRCA2 genes, which are also linked to breast cancer. Having a risk factor does not mean someone will develop this cancer, and many people who do have none.

How It's Diagnosed

Uterine carcinosarcoma usually comes to attention because of vaginal bleeding after menopause, sometimes with pelvic pain or a sense of fullness. A clinician typically examines the pelvis and orders a transvaginal ultrasound, which uses a small probe in the vagina to look at the uterine lining. The diagnosis itself requires a tissue sample, taken by an endometrial biopsy in the office or by a procedure called dilation and curettage (D&C). A pathologist looks for both carcinoma and sarcoma elements; sometimes the full picture only becomes clear once the uterus has been removed. Ovarian carcinosarcoma tends to cause vague symptoms such as bloating, feeling full quickly or bowel changes, and is usually found with imaging and confirmed at surgery. Because this cancer often spreads early, CT, MRI or PET scans are used to check the chest, abdomen and pelvis, and surgery confirms the stage. Stage runs from I (confined to the uterus) to IV (spread to distant organs), and it is the single biggest influence on treatment and outlook. Testing of the tumor itself is now recommended. Mismatch repair testing shows whether the cancer cells have lost a DNA proofreading system, which affects how well immunotherapy may work and can point to Lynch syndrome in the family. HER2 testing shows whether the cells make extra HER2, a protein that drives cell growth, in which case a medicine aimed at HER2 might help. These results are often available from the biopsy or surgical specimen.

Treatment Options

For cancer that can be removed, treatment usually begins with surgery: removal of the uterus, cervix, fallopian tubes and ovaries, along with nearby lymph nodes and often the omentum (a fatty layer in the abdomen where this cancer can spread unseen). Surgery is often done through small incisions when the cancer appears confined to the uterus. Surgery alone is rarely enough, even at an early stage, because the risk of the cancer returning elsewhere in the body is high. Chemotherapy is therefore recommended afterward for most people, usually six cycles of carboplatin and paclitaxel. This combination replaced older regimens because it worked at least as well with fewer side effects. Common effects include tiredness, hair loss, low blood counts and numbness or tingling in the hands and feet. Radiation to the pelvis or the top of the vagina may be added to lower the chance of the cancer returning there, though it has not clearly been shown to lengthen survival on its own. For advanced or recurrent cancer, tumor test results shape what is added to chemotherapy. Immunotherapy medicines that help the immune system recognize cancer, such as pembrolizumab (Keytruda) and dostarlimab (Jemperli), are approved with chemotherapy for advanced or recurrent endometrial cancer. They help most when the tumor is mismatch repair deficient, and more modestly otherwise, which describes most carcinosarcomas. For the roughly 10 to 20 percent of tumors that are HER2-positive, trastuzumab, a medicine aimed at HER2, may be added. Because results remain limited, specialists encourage clinical trials, especially for advanced disease. Ovarian carcinosarcoma is treated with surgery to remove as much cancer as possible, followed by platinum-based chemotherapy, though no single regimen has been proven best. Care is usually led by a gynecologic oncologist, a surgeon who specializes in cancers of the female reproductive organs, working with medical and radiation oncologists.

What to Expect

Carcinosarcoma is serious, and its course varies widely. Outcomes depend mostly on stage. Across published studies, about half of people with early-stage uterine carcinosarcoma were alive five years after diagnosis, compared with about one in five when the cancer had already spread. These are averages from past treatment; they cannot predict any one person's course, and newer tumor-guided treatments are still being evaluated. Treatment typically spans several months: recovery from surgery over a few weeks, then several months of chemotherapy, sometimes with radiation. Many people need practical help during this time with fatigue, appointments and household tasks. Removing the ovaries brings on menopause for anyone who has not yet reached it. After treatment, regular follow-up visits with a pelvic exam and a review of symptoms usually continue for about five years, with scans added for some people depending on risk. Most recurrences are found because a person notices a new symptom, so knowing what to report matters. Palliative care, which focuses on comfort and quality of life, can be helpful at any stage, not only near the end of life.

When to Seek Help

Make a prompt appointment with a clinician for any vaginal bleeding or spotting after menopause, even if it is light or happens once. If you take or have taken tamoxifen, report abnormal vaginal bleeding right away so it can be evaluated. Bloating, pelvic pressure or feeling full quickly that persists for more than a few weeks is also worth checking. After treatment, contact your care team soon about new vaginal bleeding, a lump, pain in the pelvis, belly or back, a lasting cough or shortness of breath, or unexplained weight loss, since these can be signs that the cancer has returned. During chemotherapy, follow your team's instructions for reporting fever, which can signal a serious infection when blood counts are low.

Questions to Ask Your Doctor

  1. 1.What stage is my cancer, and what did the tumor testing (mismatch repair, HER2) show?
  2. 2.What is the goal of each part of my treatment, and what would we expect to gain from adding immunotherapy, targeted therapy or radiation?
  3. 3.Is there a clinical trial that would be appropriate for me?
  4. 4.What follow-up schedule will I have, and which symptoms should prompt me to call before my next visit?
  5. 5.Should I or my relatives have genetic counseling for Lynch syndrome or BRCA variants?

Last reviewed • Oct 2026

Educational content, not medical advice.